[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571973":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":10,"responsibleParty":36,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MIBC patients who received NAT",null,"muscle invasive bladder cancer patients who received neoadjuvant chemotherapy",[13],"Drug: Chemotherapy with platine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Chemotherapy with platine","medical records that patients received neoadjuvant systemic chemotherapy platine based",[9],[21],{"name":22,"affiliation":5,"role":23},"Rehab Farouk Mohamed, Professor","STUDY_DIRECTOR",[25,31],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Sara Mahmoud Ahmed, resident","CONTACT","+201118247266","+201021267096","sara.mahmoud371998@gmail.com",{"name":32,"role":27,"phone":33,"phoneExt":34,"email":35},"Rehab Farouk Mohamed, professor","+201004435644","+20102126709","foroukrehab@aun.edu.eg",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Sara Mahmoud Ahmed Mahmoud","doctor","100571973","survival-benefits-of-neoadjuvant-systemic-chemotherapy-in-muscle-invasive-bladder-cancer-100571973",false,"NCT06727214","Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer","Survival Benefit of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer and Factors Affecting Its Response - Retrospective Study","AssiutU","Inclusion Criteria:\n\n* Age \\>18\n* histological proven MIBC patient treated with neoadjuvant systemic chemotherapy( platinum based )\n\nExclusion Criteria:\n\n* Non muscle invasive bladder cancer (NMIBC)\n* Metastatic patients\n* Patients treated with surgery firstly","ALL","18 Years",{"count":51,"type":52},87,"ESTIMATED","OBSERVATIONAL","Muscle-invasive bladder cancer (MIBC) is an aggressive disease with a high-risk of early metastasis and cancer specific mortality. The gold standard treatment of MIBC is radical cystectomy (RC) in conjunction with concomitant bilateral pelvic lymphadenectomy . While radical cystectomy remains a primary management strategy for MIBC, high rates of recurrence with surgery alone highlight the likelihood of occult micrometastatic disease at the time of diagnosis. Due to the development and implementation of neoadjuvant chemotherapy prior to radical cystectomy, the prognosis for MIBC patients undergoing radical cystectomy has improved .",[56],"Bladder Urothelial Carcinoma",[58,59,60],"survival benefits","neoadjuvant CTH","bladder cancer","NOT_YET_RECRUITING","2025-09-29",{"date":64,"type":65},"2025-09-30","ACTUAL",{"date":67,"type":52},"2025-11-04",{"date":69,"type":52},"2026-12-01",{"name":38,"class":6}]